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Cost-Effectiveness and Formulary Evaluation:  Imaginary Worlds and Entresto Claims in 
Heart Failure 
Paul C. Langley, PhD 
College of Pharmacy University of Minnesota 
 
Abstract 
The Program in Social and Administrative Pharmacy at the University of Minnesota recently released its proposed guidelines for 
formulary evaluation.  The guidelines were focused on ensuring that comparative claims made for pharmaceutical products and 
devices rested on a credible evidence base. The argument was put forward that if value claims for clinical and cost-effectiveness 
outcomes were to be accepted then they had to be empirically evaluable. The purpose of this commentary is to explore alternative 
modeled claims for Entresto, an angiotensin receptor neprilysin inhibitor, versus the standard of care with an ACE inhibitor in patients 
with chronic heart failure. Two models are compared: a lifetime cost-per-QALY model and a 3-year cost and budget impact model. 
The primary reason for this comparison is the puzzling feature that for a product which is over 120 time as expensive compared to the 
standard of care (Entresto $380 per month vs. ACE inhibitor $3 per month) the modeled claim can be made that the product is, in 
willingness to pay terms, cost-effective. The analysis illustrates that, perhaps not surprisingly, different models can generate quite 
different perspectives on the presumption of ‘cost-effectiveness’. In the present case the simple decision model yields a breakeven 
monthly cost for Entresto of only $23.74. If modeled claims are to be useful for formulary decision making, then we need to eschew 
‘black box’ models with non-evaluable claims in favor of those models that yield credible, evaluable and replicable claims that can 
support defensible product  placement and pricing decisions. 
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Introduction  
The Program in Social and Administrative Pharmacy at the 
University of Minnesota recently released its proposed 
guidelines for formulary evaluation 1.  The guidelines were 
focused on ensuring that comparative claims made for 
pharmaceutical products and devices rested on a credible 
evidence base. The argument was put forward that if value 
claims for clinical and cost-effectiveness outcomes were to be 
accepted then they had to be empirically evaluable 2. The 
guidelines proposed that all submissions for formulary review 
be accompanied by a protocol that proposed how the claims 
were to be evaluated and reported to a formulary committee 
in a meaningful time frame. The standards proposed were 
those of normal science: claims had to be credible, evaluable 
and replicable 3. Claims from manufacturers, even if based on 
the results of apparently well conducted randomized clinical 
trials (RCTs) were not to be taken at face value: they had to 
be replicated for target patient populations in a real world 
treating environment. Achieving these goals was seen as a 
necessary precursor to creating an outcomes based formulary 
where formulary status, contracting and pricing were 
consistent with increased accountability for quality and the 
total cost of care with the focus on population health 
management 4.  
 
Corresponding author: Paul C. Langley, PhD 
Adjunct Professor 
College of Pharmacy University of Minnesota  
Phone: 520-577-0436; Email: langley@maimonresearch.com  
Web: www.maimonresearch.com 
The purpose of this commentary is to consider as a case study 
the cost-effectiveness claims made by the Institute for Clinical 
and Economic Review (ICER) for the angiotensin receptor 
neprilysin inhibitor Entresto in surviving patients with heart 
failure 5. This commentary has been prompted by what may 
appear to be an odd situation when comparative clinical 
effectiveness is compared to differences in drug prices. 
According to the ICER report the monthly cost of Entresto is 
$380 compared to the monthly cost of Enalapril, an ACE 
inhibitor, at $3 per month. With a product more than 120 
times as costly as the existing monthly cost of the established 
standard of care, the ICER report claims Entresto to be cost-
effective at a 9% price reduction if we accept a willingness to 
pay benchmark of $50,000 per QALY.  
 
Yet the benefits conferred by Enalapril from the PARADIGM-
HF trial appear marginal: (i) a reduction from 14.3% to 12.4 % 
(absolute reduction 1.9%) in patients with worsening heart 
failure leading to intensification of outpatient therapy; (ii) a 
reduction in the number of patients with emergency 
department visits for heart failure from 208 to 151 from 
respective index enrollments of patients of 4,212 and 4,187 
respectively over some 50 months from first patient 
randomization (4.9% to 3.6%); (iii) a reduction in the number 
of patients hospitalized for heart failure from 658 to 537 
(15.6% to 12.8%); and (iv) a reduction in the average number 
of admissions per patient from 1.64 to 1.58 of those 
hospitalized 6.  
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In order to illustrate the impact of an alternative model 
framework to support claims for cost-effectiveness, the 
results of the ICER reference case model are compared to a 
simple decision model which attempts to evaluate the 
comparative clinical claims made in the PARADIGM-HF trial in 
terms of the direct medical costs likely to be incurred in 
switching patients from the ACE inhibitor Enalapril to 
Entresto. This does not mean that alternative cost-per-QALY 
models could not be constructed; the point at issue is 
whether the ICER framework meets the standards of normal 
science for experimentation and replication 7. 
 
The ICER Entresto Model 
The ICER Entresto model utilized a Markov framework to 
assess cost-effectiveness. It was designed to model or 
simulate the natural history of chronic heart failure in a 
cohort of 64-year-old-patients with New York Heart 
Association (NYHA) class II-IV heart failure with reduced 
ejection fraction based on the PARADIGM-HF trial and other 
published literature 8. Entresto was compared to lisinopril 
standard treatment. Event rates for the probabilities of 
hospitalization and mortality in the routine care comparison 
were from the PARADIGM-HF trial. The trial data also 
supported estimates of the numbers of heart failure 
hospitalizations, costs, deaths, life years and quality adjusted 
life years (QALYs). For model purposes outcomes associated 
with ACE inhibitors were considered equivalent. The model 
included switching for those intolerant to either Entresto or 
the ACE-inhibitor.  
 
The model assumed a monthly Markov time cycle with a 
lifetime horizon. Each month patients were assumed to be at 
risk for a heart failure hospitalization, angioedema requiring 
hospitalization, any other non-heart failure hospitalization, an 
ED visit for heart failure not requiring hospitalization, 
intolerance to their treatment agent and a cardiovascular or 
non-cardiovascular death. Where patients were assumed to 
be intolerant or who suffered an angioedema they were 
switched to either an ACE inhibitor for those taking Entresto 
or an ARB if intolerant to an ACE inhibitor. Transition 
probabilities between Markov states were determined from 
the events reported in the PARADIGM-HF trial. Probabilities 
of cardiovascular death were derived from the literature. 
Event costs were derived from the literature: CHF 
hospitalization from the AHRQ National Inpatient Sample. 
 
The baseline QALY estimate (0.822; range 0.705-0.938) was 
from the average EQ-5D measurement during the course of 
the trial. This estimate has not been published but was based 
on a personal communication from the manufacturer. The 
utility increment from receiving Entresto was based on the 
least squares mean of difference between the changes in 
baseline in the two arms (0.009; range 0.002-0.016). 
Exacerbations requiring an ED visit but not hospitalization 
were assumed to incur two days of disutility; a disutility of 
one day was estimated for therapy intolerance and two days 
for an angioedema requiring hospitalization. Disutilities based 
on the literature were applied for CHF hospitalization and 
non-CHF hospitalization of approximately three days in a 
monthly cycler. The model was estimated for all-patients and 
the then for two sub-groups: NYHA Class II and NYHA Class 
III/IV patients. 
 
In the all-patients base case the model predicted 6.78 years 
of survival in the ACE inhibitor arm (from initial entry of 64 
years of age) and 0.97 undiscounted CHF hospitalizations per 
patient. These compared in the Entresto arm to 7.41 years of 
survival and 0.90 CHF hospitalizations in the Entresto arm. 
The corresponding QALY estimates were 5.56 for the ACE 
inhibitor arm with total costs of $123,578 compared to 6.13 
QALYs and costs of $152,716 in the Entresto arm. The per 
patient cost on the Entresto arm was 23.6% higher than for 
those on the ACE inhibitor for these survival estimates. The 
modeled cost per QALY gained with Entresto was $50,915. If 
a willingness to pay threshold of $50,000 was assumed, 
Entresto would be deemed cost-effective at a price per 
annum of $4,464 vs. $4,560.      
 
The ICER Entresto model is the standard reference case cost-
for quality adjusted life year model that is found in its drug 
evaluation reports. It is based on the NICE reference case 
model 9. Typically, the model is not released for public review 
which means that, in practical terms, it is impossible to 
review, modify and replicate. It is the quintessential black 
box.  Previous commentaries in this series have pointed to 
the limitations of reference case models, the use of QALYs in 
modeled claims and the impossibility of evaluating these 
claims to support formulary decisions 10 11. The point to note 
is that, irrespective of claims made that reference case 
models provide a useful correspondence with the real world, 
they are imaginary constructs. It is assumed, presumably by 
those who accept this methodology in decision making, that 
the sufficient correspondence of the model and its 
assumptions with the natural history of chronic heart failure, 
necessarily entails the claims for the clinical impact of 
Entresto in this target population. Similar models could, of 
course, be built to come to quite different conclusions and, 
indeed, it would be possible to reverse engineer any 
reference case or similar model to come to conclusions that 
favor a particular product.  
 
Reference models or simulations must fail the standards or 
normal science if they present value claims for products that 
are neither evaluable nor replicable. In the absence of 
experimentation the claims are of little use to formulary 
committees in seeking real world evidence to support 
formulary listing and pricing. They are best seen as 
pseudoscience.  
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Presenting claims based on reference case models puts 
formulary committees in a quandary. The sheer complexity of 
lifetime models, their claim to be based on unevaluable 
model standards that are approved by agencies such as the 
Academy of Managed Care Pharmacy (AMCP) in their Format 
for Formulary Submissions and the International Society for 
PharmacoEconomics and Outcomes Research (ISPOR) 
together with blanket claims that the particular product is 
‘cost-effective’ is to ask formulary committees to take the 
claims at face value 12 13 14.  A situation that is not helped by 
the willingness of journal editors to publish modeled yet 
untestable cost-effectiveness claims for drugs and devices 15. 
 
The risk, as exemplified by the Entresto case, is that claims 
that the product is ‘cost-effective’ are taken at face value 16. 
This is not helped by the lack of transparency in descriptions 
of the modeling framework. As a result, integrated health 
delivery systems, pharmacy benefit management groups and 
other health systems run the risk of entering into contracts 
that have the potential to incur significant drug costs for, 
possibly, minor clinical benefits in the target treating 
population. Untestable claims generated by imaginary worlds 
are not a basis for formulary decision making. 
 
An Imaginary Reconfiguration   
The most puzzling feature of the ICER assessment of Entresto 
for heart failure hospitalization is how a product that is over 
120 times as expensive as the ACE inhibitor standard of care 
($380 vs. $3 per month) in surviving patients with heart 
failure  can be considered to be cost-effective 17. In order to 
examine the merits of this claim, a simple decision budget 
impact model is proposed that evaluates the direct medical 
costs of emergency room visits and hospitalizations for heart 
failure over a 3 year time frame. The estimated direct medical 
costs are compared to the number of emergency room visits 
and hospitalizations avoided  to give a cost per event avoided 
together with an estimated breakeven  monthly cost for 
Entresto where transitioning patients to the new drug has a 
zero impact on the overall costs of care. The model is 
constructed in Excel and a copy of the model is provided as a 
simple spreadsheet in Appendix A to this commentary. 
 
The model has been configured to reproduce the results for 
the total number of emergency department visits and 
hospitalizations (HF Events) reported from the PARADIGM-HF 
trial, adjusted for 10,000 patients in each of the Entresto and 
ACE arms over an arbitrary 3-year period. It should be 
emphasized that the model is concerned with orders of 
magnitude, not claims that can be defended as valid to the 
nearest dollar. A number of the assumptions are only 
considered ‘reasonable’ as more detail from the Entresto trial  
are unavailable. Unlike the ICER model the one proposed 
here includes emergency room visits as well as 
hospitalization. It also attempts to take account of non-
persistence with therapy. It is assumed that adherence is not 
an issue. The model is not concerned with utility measures, 
quality of life or willingness-to-pay thresholds as the 
justification for claiming cost-effectiveness and 
recommending a price consistent with that threshold. 
 
Six patient groups are modeled for each intervention arm. 
These are:   
• Group A: Patients who are adherent to therapy 
throughout 3 year forecast period with no heart 
failure (HF) related events (ED or hospitalizations 
• Group B: Patients who were not persistent with 
therapy (dropped out before end of 3 year period) 
but who had no HF related events  
• Group C: Patients who were adherent to therapy 
with events before end of 3 year period 
• Group D: Patients who were not persistent with 
therapy who experienced HF related events before 
dropping out 
• Group E: Patients who were persistent with therapy 
but who and died without HF events  
• Group F: Patients who were persistent with therapy 
but who experienced HF events before death 
In all cases, where patients were not persistent or who died 
(Groups B, D, E and F), this was assumed to occur on average 
after 18 months of treatment with the respective therapies.  
 
Costs for the HF events were $12,832 for a hospitalization 
and $1,000 for an emergency room visit. Monthly drug costs 
were assumed to be $380 for Entresto and $3 for the ACE 
inhibitor. All costs were assumed to remain unchanged over 
the 3-year period. Apart from the emergency room costs, 
these costs are from the ICER model. 
 
Table 1 details for the 6 patient groups assumptions for (i) the 
number of emergency care and hospitalizations per patient 
over the 3 year period (Group C) and the 18 months prior to 
dropout (Groups D and F) for Entresto and the ACE inhibitor 
arm respectively and (ii) the distribution of patients between 
the 6 groups at the index prescription for both product arms. 
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Table 1 
Heart Failure Events and Patient Distribution by Drug Utilization Group 
 
Patient Group Entresto: ER 
visits/3 
years/18 
months 
ACE: ER visits/3 
years/18 
months 
Entresto: 
Hospitalizations 
/3 years/18 
months 
ACE: 
Hospitalizations/3 
years/18 months 
Patient 
Distribution 
A     0.4 
B     0.19 
C* 0.15 0.24 1.5 1.8 0.08 
D** 0.06 0.09 0.4 0.5 0.03 
E      0.15 
F** 0.06 0.09 0.4 0.5 0.15 
Note: *3 year time frame; **18 month time frame; event frequency and patient distribution from Appendix A 
 
 
Results 
The model results are summarized in Table 1 below:  
 
i. Medical Costs: Weighted by the distribution of index 
patients across the 6 groups the total direct medical 
costs for an assumed 10,000 index patients are 
Entresto $126,097,440 and the ACE inhibitor 
$31,180,080. An increase in costs of $94,917,360 (or 
$94,917 per patient) or weighted  per patient 
$12,609 and $3,118 respectively 
ii. Drug Costs: Drug costs in the Entresto arm account 
for 80.3% of total costs; in the ACE arm 2.6% 
iii. HF Events avoided from switching to Entresto : for 
the 10,000 index patients are 96 emergency 
department visits and 420 hospitalizations 
iv. Cost per HF hospitalization for 10,000 index patients: 
Entresto - $65,675; ACE - $13,325 
v. Cost per ER visit for 10,000 index patients: Entresto - 
$488,749; ACE – 88,079 
vi. Direct Medical Cost per HF event avoided by 
switching to Entresto: emergency room visit 
$998,722 per patient and hospitalizations $225,993 
per patient  
vii. Cost differential: over the 3 year time horizon the 
ratio of Entresto to ACE total costs is 4.04 
viii. Breakeven price of Entresto when switching yields 
same total cost as the ACE inhibitor: $23.74 per 
month 
Discussion 
A product is cost-effective only if the payer considers it to be 
cost-effective. Irrespective of the ICER use of reference case 
cost-per-QALY model and $50,000 cost per QALY thresholds, 
there are no agree standards for judging whether a cost-per-
outcome estimate is meaningful to a payer. The ICER model 
builds an imaginary reference case cost-per-QALY world to 
justify its claim for cost effectiveness. In the report on 
Entresto, ICER judged (on a $50,000 willingness-to-pay 
threshold) that Entresto would be cost effective for any payer 
if Novartis reduced price by 9%. The imaginary world analysis 
above suggests that a price reduction of over 90% might be 
more appropriate with a monthly breakeven price of $23.75.  
 
The differences in total treatment costs are marked. With an 
assumed 10,000 patients initiated to therapy on each arm, 
over 3 years total costs increase from $31.2 million to $126.1 
million (just over 4 times). On the event assumptions built 
into the model for illustrative purposes, to achieve a 
reduction in 96 ER events and 420 hospitalizations, the cost 
per event saved in adopting Entresto is $998,722 and 
$225,993 per event (not per patient) respectively. It is also 
worth noting that in the ICER model, the direct medical 
(including pharmacy) costs for Entresto are only 23.6% 
greater than for the ACE inhibitor while in the 3-year 
illustrative model the difference is over 304.4% greater. It is 
not clear from the ICER model why the cost differential is 
relatively small given the magnitude of the difference in drug 
costs. If a health system considers these costs acceptable, it 
should be kept in mind that all decisions to support new 
products involve opportunity costs, benefits forgone to 
patients in other disease and therapy areas.  
 
Unevaluable claims based on imaginary worlds should not be 
a guide to either formulary decisions or contracts for product 
pay-for-performance. In the absence of value claims for 
products that are evaluable and replicable, claims should be 
put to one side until a manufacturer can put forward 
evaluable claims that are credible and can be reported back 
to formulary committees in a meaningful time frame. The 
model presented here is intended as an illustration of a 
counterpoint to lifetime cost-per-QALY models. It has two 
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advantages (i) the model is transparent and (ii) all 
assumptions and predictions are verifiable. Simple 
spreadsheet models are not new; what is new, unfortunately, 
is a trend towards the specification of more complex models 
which are not only a ‘black box’ to formulary committees but 
which are incapable of supporting evaluable claims. At the 
same time these models may embed value benchmarks in 
their assessments of cost-effectiveness which, like other 
assumptions built into the models, may be unacceptable to 
the intended audience.  
 
Conclusions 
In the US there are no agreed standards for value 
benchmarks in modeled claims for cost-effectiveness. Indeed, 
attempts to put cost-per-QALY benchmarks in place have 
been excluded for evaluations falling under the umbrella of 
the Patient Protection and Affordable Care Act. While 
unintended, this decision may be seen in retrospect as 
eminently sensible as it may act as a brake on the enthusiasm 
for developing and publishing ‘black box’ lifetime cost-per-
QALY models in order to justify product placement and 
pricing. Modeled claims which, in probably the overwhelming 
majority of cases, are put to one side by formulary 
committees as of limited (if any) application in formulary 
decision making. After all, if the formulary committee, in the 
absence of evaluable claims being presented, has no idea 
whether the claims are right or even if they are wrong, it is 
then perhaps unsurprising that an independent observer 
might see these endeavors as a waste of time and resources.. 
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